Nanjing Well Pharmaceutical Group Co.,Ltd.

XSSC:603351 Stock Report

Market Cap: CN¥3.3b

Nanjing Well Pharmaceutical GroupLtd Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Renrong Wu

Chief executive officer

CN¥990.7k

Total compensation

CEO salary percentagen/a
CEO tenure4.6yrs
CEO ownership13.7%
Management average tenureno data
Board average tenure4.6yrs

Recent management updates

Recent updates


CEO

Renrong Wu (61 yo)

4.6yrs

Tenure

CN¥990,700

Compensation

Mr. Renrong Wu is Chairman, Director & CEO of Nanjing Well Pharmaceutical Group Co.,Ltd. from April 08, 2020. He joined the Nanjing Well Pharmaceutical Group Co.,Ltd.in February 2000.


Board Members

NamePositionTenureCompensationOwnership
Renrong Wu
Chairman & CEO4.6yrsCN¥990.70k13.68%
CN¥ 447.9m
Zhengsong Gao
Director4.6yrsCN¥825.60k10.42%
CN¥ 341.2m
Xinguo Chen
Director & VP4.6yrsCN¥825.60k10.42%
CN¥ 341.2m
Yamei Guan
Independent Director1.5yrsCN¥49.70kno data
Rongwen Wu
Chairman of the Supervisory Board4.6yrsno data2.2%
CN¥ 72.1m

4.6yrs

Average Tenure

58yo

Average Age

Experienced Board: 603351's board of directors are considered experienced (4.6 years average tenure).